Blood pressure lowering after experimental cerebral ischemia provides neurovascular protection

Journal of Hypertension

Volumn 25, Issue 4, 2007, Pages 855-859

  Elewa, Hazem F ^a,c   Kozak, Anna ^a,c   Johnson, Maribeth H ^b   Ergul, Adviye ^a,b   Fagan, Susan C ^a,b,c  

^a UNIVERSITY OF GEORGIA   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Blood pressure; Neurovascular protection; Stroke

Indexed keywords

ENALAPRIL; HEMOGLOBIN; HYDRALAZINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; BRAIN FUNCTION; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; BRAIN PERFUSION; BRAIN PROTECTION; BRAIN TISSUE; CONTROLLED STUDY; DRUG EFFECT; HEMOGLOBIN DETERMINATION; MALE; MEDICAL ASSESSMENT; MIDDLE CEREBRAL ARTERY OCCLUSION; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION; STROKE; TELEMETRY; THERAPY EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; AREA UNDER CURVE; BENZIMIDAZOLES; BIOLOGICAL MARKERS; BLOOD PRESSURE; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; CIRCADIAN RHYTHM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; HEMOGLOBINS; HYDRALAZINE; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; RATS; RATS, WISTAR; REPERFUSION; TELEMETRY; TETRAZOLES;

EID: 33947109482     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e3280149708     Document Type: Article

References (23)

1. Willmot M, Leonardi-Bee J, Bath PM. High blood pressure in acute stroke and subsequent outcome: a systematic review. Hypertension 2004; 43:18-24.
2. Spengos K, Tsivgoulis G, Zakopoulos N. Blood pressure management in acute stroke: a long-standing debate. Eur Neurol 2006; 55:123-135.
3. Fagan SC, Kozak A, Hill WD, Pollock DM, Xu L, Johnson MH, et al. Hypertension after experimental cerebral ischemia: candesartan provides neurovascular protection. J Hypertens 2006; 24:535-539.
4. Hosomi N, Nishiyama A, Ban CR, Naya T, Takahashi T, Kohno M, Koziol JA. Angiotensin type 1 receptor blockage improves ischemic injury following transient focal cerebral ischemia. Neuroscience 2005; 134:225-231.
5. Fournier A, Achard JM, Boutitie F, Mazouz H, Mansour J, Oprisiu R, et al. Is the angiotensin II type 2 receptor cerebroprotective? Curr Hypertens Rep 2004; 6:182-189.
6. Iwai M, Liu HW, Chen R, Ide A, Okamoto S, Hata R, et al. Possible inhibition of focal cerebral ischemia by angiotensin II type 2 receptor stimulation. Circulation 2004; 110:843-848.
7. Saavedra JM, Benicky J, Zhou J. Mechanisms of the anti-ischemic effect of angiotensin II AT(1) receptor antagonists in the brain. Cell Mol Neurobiol 2006; in press.
8. Longa EZ, Weinstein PR, Carlson S, Cummins R. Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke 1989; 20:84-91.
9. Bederson JB, Pitts LH, Tsuji M. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke 1986; 17:472-476.
10. Hilali HM, Simkins AN, Hill WD, Walter JL, Knight RA, Fagan SC. Single slice method for quantification of hemorrhagic transformation using direct ELISA. Neurol Res 2004; 26:93-98.
11. Ando H, Zhou J, Macova M, Imboden H, Saavedra JM. Angiotensin II AT1 receptor blockade reverses pathological hypertrophy and inflammation in brain microvessels of spontaneously hypertensive rats. Stroke 2004; 35:1726-1731.
12. Eguchi K, Kario K, Shimada K. Beneficial effect of ARB for ischemic stroke [in Japanese]. Nippon Rinsho 2002; 60:1987-1991.
13. Engelhorn T, Goerike S, Doerfler A, Okorn C, Forsting M, Heusch G, Schulz R. The angiotensin II type 1-receptor blocker candesartan increases cerebral blood flow, reduces infarct size, and improves neurologic outcome after transient cerebral ischemia in rats. J Cereb Blood Flow Metab 2004; 24:467-474.
14. Groth W, Blume A, Gohlke P, Unger T, Culman J. Chronic pretreatment with candesartan improves recovery from focal cerebral ischaemia in rats. J Hypertens 2003; 21:2175-2182.
15. Daiber A, Mülsch A, Hink U, Mollnau H, Warnholtz A, Oelze M, Münzel T. The oxidative stress concept of nitrate tolerance and the antioxidant properties of hydralazine. Am J Cardiol 2005; 96:25i-36i.
16. Daiber A, Oelze M, Coldewey M, Kaiser H, Huth C, Schildknecht S, et al. Hydralazine is a powerful inhibitor of peroxynitrite formation as a possible explanation for its beneficial effects on prognosis in patients with congestive heart failure. Biochem Biophys Res Commun 2005; 338:1865-1874.
17. Knowles HJ, Tian YM, Mole DR, Harris AL. Novel mechanism of action for hydralazine: induction of hypoxia-inducible factor-1alpha, vascular endothelial growth factor, and angiogenesis by inhibition of prolyl hydroxylases. Circ Res 2004; 95:162-169.
18. Leiro JM, Alvarez E, Arranz JA, Cano E, Ovallo F. Antioxidant activity and inhibitory effects of hydralazine on inducible NOS/COX-2 gene and protein expression in rat peritoneal macrophages. Int Immunopharmacol 2004; 4:163-177.
19. Brasier AR, Recinos A III, Eledrisi MS. Vascular inflammation and the renin-angiotensin system. Arterioscler Thromb Vasc Biol 2002; 22:1257-1266.
20. Di Napoli M, Papa F. Angiotensin-converting enzyme inhibitor use is associated with reduced plasma concentration of C-reactive protein in patients with first-ever ischemic stroke. Stroke 2003; 34:2922-2929.
21. Chillon JM, Baumbach GL. Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arteriolar dilatation in hypertensive rats. Hypertension 2001; 37:1388-1393.
22. Demolis P, Carville C, Giudicelli JF. Effects of an angiotensin- converting enzyme inhibitor, lisinopril, on cerebral blood flow autoregulation in healthy volunteers. J Cardiovasc Pharmacol 1993; 22:373-380.
23. Nazir FS, Overell JR, Bolster A, Hilditch TE, Lees KR. Effect of perindopril on cerebral and renal perfusion on normotensives in mild early ischaemic stroke: a randomized controlled trial. Cerebrovasc Dis 2005; 19:77-83.